GlassScriptPhysician profile
Shahla Mallick
NPI 1629025804
$4,980.92
in general payments reported to CMS, 2019-2025
23 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $262 · 2021: $222 · 2022: $949 · 2023: $859 · 2024: $859 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.01 |
| Education | $170.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,342.39 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,232.56 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $527.14 | 2022-2025 | Dupixent |
| Genzyme Corporation | $340.77 | 2020-2025 | |
| Astellas Pharma US INC | $319.96 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.94 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $159.79 | 2021-2024 | Glassia |
| Gilead Sciences, INC. | $124.94 | 2019 | |
| Electromed, INC. | $109.63 | 2022-2025 | Smartvest |
| Insmed, INC. | $79.29 | 2025 | Arikayce |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| United Therapeutics Corporation | $64.63 | 2023-2024 | Tyvaso |
| Genentech USA, INC. | $64.59 | 2019-2022 | |
| Viatris Specialty LLC | $39.53 | 2025 | Yupelri |
| Grifols USA, LLC | $39.45 | 2023-2025 | Prolastin-C Liquid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $35.61 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $32.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.74 | 2022-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $22.49 | 2019 | |
| Breathe Technologies, INC. | $18.93 | 2019 | |
| Mylan Specialty L.P. | $18.65 | 2024 | Yupelri |
| Masimo Corporation | $18.43 | 2025 | Set and Rainbow Set |
| Amgen INC. | $16.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahla Mallick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.